WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 05-Dec-2014 (Data received as of 1-Dec-2014)
Next overall update June 2015
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 122
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 152

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 21'898  21'890  21'804  21'533  21'032  16'371  12'452  8'956 
Births 532  529  526  523  519  496  445  400 
Surviving infants 522  520  518  514  510  486  432  380 
Pop. less than 5 years 2'588  2'624  2'644  2'640  2'626  2'399  2'137  1'753 
Pop. less than 15 years 7'684  7'738  7'752  7'695  7'631  6'681  5'842  4'363 
Female 15-49 years 5'582  5'594  5'590  5'538  5'395  4'062  2'710  1'847 

Number of reported case

(Click for retrospective incidence data for Syrian Arab Republic (the))
Diphtheria 80  366 
Japanese encephalitis
Measles 740  13  13  26  22  146  535  1'478 
Mumps 45  52  95  145  144  7'780 
Pertussis 35  90  70  19  124  39  430 
Polio* 35  13  312 
Rubella 20 
Rubella (CRS)
Tetanus (neonatal) 15  55  91 
Tetanus (total) 13  17  71  244 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Syrian Arab Republic (the))
Vaccine year result method % card seen                                                
BCG 2008  93  PAPFAM   66  86  84  99*  100  100  100  92  35 
DTP1 2008  88  PAPFAM   66  66  79  97  100  100  98  93 
DTP3 2008  82  PAPFAM   66  60  64  91  99  99  97  91  13 
HepB_BD          84  83  98  100  100  100 
HepB3 2005  77  MICS   55  86  58  81  99  99  90 
Hib3          60  64  91  99 
JapEnc         
MCV 2008  82  PAPFAM   66  83  78  97  99  99  96  87  13 
MCV2          75  70  88  99  99  92 
PCV1         
PCV3         
Pol3 2008  81  PAPFAM   66  80  68  91  99  99  97  91  13 
Rota1         
Rota_last         
Rubella1          83  78  97 
TT2plus 1989  51  EPI   70  10  11  16  28  23  20  63 
PAB         
VAD1          64  78  59  90  99  94 
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Syrian Arab Republic (the))
BCG 84  82  90  97  95  91  92  35 
DTP1 55  68  86  89  89  90  93  35 
DTP3 41  45  72  80  80  84  91  13 
HepB3 71  43  66  84  84  79 
HepB_BD 81  81  89  97  95  91 
Hib3 41  45  72  80  80 
MCV 61  61  80  82  82  84  87  13 
MCV2 58  53  71  82  82  80 
PAB 94  94  94  94  94  90  63 
PnC3
Pol3 52  52  75  83  83  86  91  13 
Rota_last

Number of districts in the country 75  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
87 
   
/
|
|
\
Greater or equal to 90% 0
From 80 to 89% 20
From 50 to 79% 80
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT 6 years; Yes
DTaPHibIPV 2, 4, 6, 18 months; Yes according the availablility of vaccines
DTwPHib 2, 4, 6, 18 months; Yes according the availablility of vaccines
DTwPHibHepB 2, 4, 6, 18 months; according the availablility of vaccines
HepB birth; 2, 6 months; Yes
IPV 2, 4 months;
MMR 12, 18 months; Yes
MenACWY 6 years; Yes
OPV 6, 12, 18 months; Yes
TT 1st contact ; +1, +6 months; +1, +1 year; Yes CBAW
Td 12 years; Yes
VitaminA 12, 18 months; Yes

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number 2013-2014  2011-2012  2006-2011  2006-2010  2006-2010  2006-2010  2008-2010 
Nº of districts with microplans that include activities to raise immunization coverage number 75  75  75  75  71  71   

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes       

System performance

Total Nº districts in country number 75  75  75  75  71  71  71 
Nº districts with DTP3 coverage >=80% number 15  75  71  71 
% of districts with DTP3 coverage >=80% From 0 to 100% 20  100  100  100 
Nº districts with measles (MCV1) coverage >=95% number   75    63   
% of districts with MCV1 coverage >=95% From 0 to 100%   100    89   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes  Yes       
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100% 100  100    103  100  100  100 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.